Introduction: Despite the crucial role of endothelial progenitor cells (EPCs) in vascular regeneration, the specific interactions between EPCs and hematopoietic cells remain unclear.
Methods:
In EPC colony forming assays, we first demonstrated that the formation of EPC colonies was drastically increased in the coculture of CD34 + and CD34 2 cells, and determined the optimal concentrations of CD34 + cells and CD34 2 cells for spindle-shaped EPC differentiation.
Results: Functionally, the coculture of CD34 + and CD34 2 cells resulted in a significant enhancement of adhesion, tube formation, and migration capacity compared with culture of CD34 + cells alone. Furthermore, blood flow recovery and capillary formation were remarkably increased by the coculture of CD34 + and CD34 2 cells in a murine hind-limb ischemia model. To elucidate further the role of hematopoietic cells in EPC differentiation, we isolated different populations of hematopoietic cells. T lymphocytes (CD3 + ) markedly accelerated the early EPC status of CD34 + cells, while macrophages (CD11b + ) or megakaryocytes (CD41 + ) specifically promoted large EPC colonies.
Conclusion:
Our results suggest that specific populations of hematopoietic cells play a role in the EPC differentiation of CD34 + cells, a finding that may aid in the development of a novel cell therapy strategy to overcome the quantitative and qualitative limitations of EPC therapy.
Introduction
Endothelial progenitor cells (EPCs) contribute to the neovascularization in response to ischemic signals, and have been reported as potential biomarkers of cardiovascular disease [1] [2] [3] [4] [5] [6] . Although EPC therapy has been studied as a new strategy in regenerative medicine, various methods of culture of different EPC populations with distinct properties have been explored in the study and management of ischemic diseases [7] [8] [9] [10] . Several studies examining ischemic sites have reported that different types of transplanted EPCs promoted a robust vascular regeneration and were therapeutic in ischemic vascular disease [11] [12] [13] [14] [15] . Although many investigators speculate that EPCs are responsible for the modest effects observed in ischemic disease, little is known about the actual mechanism of EPC differentiation.
Research on human EPCs has been ambiguous, mainly owing to the lack of a precise definition of EPC and proper EPC assay. Recently, EPCs have been qualified and quantified by cell-surface markers including CD34, CD133, and vascular endothelial growth factor receptor-2 (VEGFR-2) [16] , or conventional EPC culture methods including EPC culture assay, CFU-EC colony assay, and endothelial colony forming cell (ECFC) assay from several primary blood samples such as peripheral blood, bone marrow, or umbilical cord [10] . These assays have contributed to the evaluation of the developmental and vasculogenic properties of EPCs, but have been disputed regarding the quality, quantity, and identification of primary circulating EPCs [17] . Our group has developed a new clonogenic assay system, which is a modification of a conventional methylcellulose assay used for identification of stem and progenitor cells [18] . This novel EPC-colony forming assay (EPC-CFA) allows an assessment of the fundamental and proper qualification and quantification of EPCs [18] [19] [20] . The EPC-CFA discriminates between two types of EPC colonyforming units (EPC-CFUs), such as small EPC-CFUs, which present proliferative capabilities, and large EPC-CFUs, which present vasculogenic properties.
Putative endothelial cell progenitors or angioblasts were isolated from human peripheral blood based on their expression of CD34 [1] , a molecule expressed by hematopoietic stem cells, hematopoietic progenitor cells, and microvascular endothelial cells. In several studies, the use of CD34 + cell populations in vascular regeneration therapy has been performed in various preclinical and clinical trials [21] [22] [23] [24] [25] [26] [27] . CD34
+ cells markedly accelerated the rate of restoration of blood flow to the ischemic limb, while CD34
2 cells produced no effect [21, 28] . Nevertheless, the significance of CD34 2 cell populations has been highlighted. Considering these findings, we focused on cross talk between CD34 + cells and CD34 2 cells and determined their importance in EPC differentiation using the EPC-CFA, which is a novel method to assess the EPC colony-forming potential of stem cells. We also evaluated the functional properties of EPC-CFUs, such as adhesion, tube formation, and migration, and their functional recovery in a murine hind-limb ischemia model on the basis of the presence of CD34 2 populations. Furthermore, we investigated which population of CD34 2 cells affects the differentiation of CD34 + cells into EPCs. This study clarified whether specific cross talk between CD34 + cells and hematopoietic cells regulates CD34 + cell differentiation into EPCs.
Materials and Methods

Animals
Experiments were performed on male 8-wk-old Balb/C nude mice (Biogenomics, Seoul, Korea, http://www.orient.co.kr) maintained under a 12-hour light/dark cycle and in accordance with the regulations of Pusan National University. The protocols were approved by the Institutional Animal Care and Use Committee of Pusan National University School of Medicine, based on the Guide for the Care and Use of Laboratory Animals.
Ethical statement
After obtaining informed, written consent, human umbilical cord blood was collected from healthy volunteers according to a protocol approved by the Ethics Review Board of the Hospital of the Pusan National University of YangSan, Korea. The Institutional Animal Care and Use Committee of Pusan National University, YangSan, Korea approved all surgical interventions and post-operative animal care. The approved protocol number is IACUC090017.
Isolation of CD34
+ cells
Human umbilical cord blood (HUCB) was supplied by the Pusan National University Hospital. CD34 + cells were isolated from HUCB as reported previously [20] . Briefly, total mononuclear cells (MNCs) were isolated by Ficoll (GE Healthcare, Buckinghamshire, U.K.) density gradient centrifugation of the cord blood. The CD34 + cells were separated from MNCs using magnetic-activated cell sorting (MACS) (CD34 + Microbead Kit; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions, to a final purity of more than 98%.
EPC colony-forming assay
Human CD34
+ , CD34 2 , or both CD34 + and CD34 2 cells isolated from HUCB were cultured in methylcellulose-containing medium, H4236 (StemCell Technologies, Vancouver, Canada), supplemented with 20 ng/mL stem cell-derived factor (Kirin, Tokyo, Japan), 50 ng/mL vascular endothelial growth factor (VEGF; R&D Systems, Minneapolis, MN, USA), 20 ng/mL interleukin (IL)-3 (Kirin), 50 ng/mL basic fibroblast growth factor (bFGF; Wako, Osaka, Japan), 50 ng/mL epidermal growth factor (EGF; Wako), 50 ng/mL insulin-like growth factor (IGF)-1 (Wako), 2 U/mL heparin (Ajinomoto, Tokyo, Japan), and 10% fetal bovine serum (FBS; Life Technologies, Carlsbad, CA) on a 35-mm dish (Thermo SCIENTIFIC, Rockford, IL) for 8 d. The cell density of each sample was 5610 2 cells per dish or was adjusted depending on the assay. The EPCs were identified as small EPC-CFUs or large EPC-CFUs by visual inspection using a light microscope (OLYMPUS, Tokyo, Japan) under 40x magnification. Small EPC-CFUs were composed of round adhesive cells, and large EPC-CFUs were composed of spindle-shaped cells. Nonattached cells were isolated as small EPCs by washing with PBS (WELGENE, Daegu, Korea), while attached cells were harvested as large EPCs by treatment with 5 mM EDTA (SigmaAldrich, St. Louis, MO) in PBS (5 mmol/L) for 5 min at 37uC.
EPC-CFU staining
After 8 days in culture, the EPC-CFU cultures were treated with 0.4 mg/mL 1,19-dioctadecyl-3,3,39,3-tetramethyl-indocarbocyanine perchlorate-labeled acLDL (acLDL-DiI; Biomedical Technologies Inc., Stoughton, MA) for 1 h and fixed by application of 1 mL of 2% paraformaldehyde (PFA) (Affymetrix, Santa Clara, CA) for 1 h at room temperature. After washing with methylcellulose-PBS, the cultures were reacted with fluorescein isothiocyanate (FITC)-conjugated lectin from Ulex europaeus (UEA-I; Sigma-Aldrich) for 1 h at room temperature. The cultures were washed with PBS and then imaged using a confocal fluorescence microscope (Olympus).
Coculture analysis
Coculture analysis was performed in 12-well Millicell Cell Culture Plates (0.4 mm pore size; Millipore, Billerica, MA, USA) using Stem Span serum-free medium (StemCell Technologies), supplemented with 50 ng/mL VEGF, 20 ng/mL IL-6 (R&D Systems), 100 ng/mL SCF (Kirin), 20 ng/mL thrombopoietin (TPO; Wako), 100 ng/mL Flt-3 ligand (Wako), and 1% penicillinstreptomycin (WELGENE). Human CD34 + cells isolated from HUCB were seeded in the lower compartment of the transwell, and the transwell membrane inserts were seeded with human CD34 2 cells isolated from HUCB or left unseeded. To measure the EPC-CFU potential of CD34 + cells after coculture, the transwell inserts were removed after 7 d. The expansion of CD34 + cell was determined by cell counting.
Adhesive assay
Ninety-six-well culture plates were coated with human fibronectin (100 mg/mL; Life Technologies). EPC-CFUs (1610 4 cells per well) were allowed to attach in endothelial basal medium 2 (EBM-2; Lonza, Walkersville, MD) supplemented with 5% fetal bovine serum (FBS; Lonza), human vascular endothelial growth factor (hVEGF; Lonza), human basic fibroblast growth factor (bFGF; Lonza), human epidermal growth factor (hEGF; Lonza), human insulin-like growth factor 1 (hIGF-1; Lonza), ascorbic acid (Lonza), and GA-1000 (Lonza) (EGM-2; Lonza) for 20 min at 37uC, and the nonadherent cells were then aspirated. The adherent cells were measured after 4 h of incubation with detection reagents using the Cell Counting Kit-8 (DOJINDO, Kumamoto, Japan) with detection at 490 nm using a microplate reader (Tecan, Mä nnedorf, Switzerland).
Tube formation assay
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza and were cultured in EGM-2 following the supplier's instructions. Each group-media only, CD34
+ cells, mixed CD34
+ and CD34 2 cells, CD34 + cell culture medium, or mixed CD34
+ and CD34 2 cell culture medium-was mixed with a sample of HUVECs (with a ratio of cell fractions of each group to HUVEC of 1610 3 to 1.2610 4 cells in a 50-ml volume of 2% FBS in EBM-2) was seeded onto a 96-well plate (Thermo SCIENTIF-IC) coated with Matrigel (10 mg/mL, BD Biosciences, San Diego, CA) and further incubated for 8 h. After incubation, the number of branching points was counted using one picture per well at 40x magnification by light microscopy.
Migration assay
The migration capacity of HUVECs in response to CD34 2 cells was measured using the Boyden chamber assay (Cell Biolabs, San Diego, CA). Cells ( 3610 5 ) were placed in the upper part of a Boyden chamber. The chamber was placed in a 24-well culture dish (Thermo SCIENTIFIC) containing EBM-2, EGM-2, or 
EGM-2 containing CD34
2 cells for 24 h at 37uC. For quantification, cells migrating to the lower chamber were counted in 5 random microscopic fields using a hemocytometer (Marienfeld Superior, Lauda-Königshofen, Germany). Results are expressed as the number of migrated cells per 300,000 cells added to the Boyden chamber.
Cell transplantation in a hind-limb ischemia murine model
All procedures were performed in accordance with the policies of the Pusan National University of Korea institutional animal care and use committee. In the hind-limb ischemia murine model, ischemia was induced by ligating the proximal femoral artery and boundary vessels of 8-wk-old Balb/C nude mice. No later than 6 h after operation, CD34
+ or CD34 + /CD34 2 cell-derived EPCCFUs in PBS were transplanted via intramuscular injection into the ischemic thigh area (5610 5 cells/100 mL PBS per mouse), and blood perfusion using laser Doppler perfusion imaging (LDPI; Moor Instruments, Wilmington, DE) and capillary density by immunohistochemistry for rabbit polyclonal mouse-specific antiplatelet-endothelial cell adhesion molecule 1 (anti-PECAM-1; CD31, Santa Cruz Biotechnology, Santa Cruz, CA) were assessed. For cell tracking analysis, transplanted human EPC-CFUs were labeled with anti-human nuclei monoclonal antibody (anti-HNA; Millipore).
Flow cytometry analysis
Several subpopulations were isolated from HUCB CD34 2 cells to assess their EPC-CFU capacity in coculture with CD34 + cells. Each subpopulation (of macrophages, T cells, B cells, megakaryocytes, and monocytes) was isolated using a sterile live cell flow cytometry sorter (BD FACSAria; BD Biosciences) using labeled anti-human CD11b, CD3, CD19, CD41, and CD14 antibodies (BD Biosciences). To characterize EPC-CFUs, small and large EPC-CFUs were labeled with anti-human CD11b, CD14, CD45, and CD144 antibodies (BD Biosciences), and analyzed. 
Statistical analysis
The statistical comparison of the 2 groups was performed using Student's t-test. The results were analyzed using the Statview 5.0 software package (Abacus Concepts, Inc., CA). Scheffé's test was performed for multiple comparisons between each group after ANOVA. All data, which were obtained from at least 3 independent experiments, were expressed as means 6 standard deviation. 
Results
Differential status of EPC development in response to HUCB CD34
+ and CD34 2 cells
To determine the status of EPC development of CD34
2 , or mixed CD34 + and CD34 2 cells isolated from HUCB, we first established a novel EPC colony-forming assay (EPC-CFA) as described previously (2,000 CD34 + or CD34 2 cells per 35 mm well) [18] . EPC colony-forming units (EPC-CFUs) formed 2 types of clusters, small EPC-CFUs and large EPC-CFUs. Small EPCCFUs contained mainly small and round adhesive cells, whereas large EPC-CFUs contained spindle-shaped cells ( Figure 1A ). FACS analysis was performed to characterize each EPC-CFU. Small and large EPC-CFUs expressed surface markers of monocytic lineages: CD11, CD14, and CD45. Large EPC-CFUs expressed the endothelial marker, CD144, but small EPC-CFUs did not ( Figure S1 ). In the EPC-CFA, we determined the EPC colony-forming potential of CD34 + , CD34 2 , or mixed CD34 + and CD34 2 cells ( Figure 1B ). The number of small EPC-CFUs was not significantly different when comparing the CD34 + cells and (Figure 2A ), whereas the frequencies of large and total EPC colonies were significantly increased in coculture of CD34 + cells with CD34 2 cells compared with CD34
+ -only cell culture ( Figure 2B and C). cells (500 cells per dish) with various ratios of CD34 2 cells-50, 20, 10, 5, 2.5, 1.7, 1.25, 1, 0.3, and 0% of CD34 + cells-we assessed 2 types of EPC colony-forming potentials by measuring the frequency of EPC-CFUs. No correlation was observed between small EPC colony-forming capacity and an increase in the CD34 2 cell number ( Figure 3A) . On the other hand, coculture of 1.25% CD34 + cells with CD34 2 cells showed the highest large and total EPC colony-forming capacity among the groups (Figures 3B and  C) . These results indicate that an optimal ratio between CD34 + and CD34
2 cells is important in promoting EPC differentiation.
Assessment of the functional capacity of EPC-CFUs in response to CD34 2 cells
To determine the effect of CD34 2 cells on CD34 + cells, we examined the functional capacity of EPC-CFUs, including proliferation and the capacity for adhesion, tube formation, and migration. We performed a transwell coculture assay to characterize the paracrine effect of CD34 2 cells on the proliferation of CD34 + cells ( Figure 4A ). The proliferation ratio was approximately 2-fold higher when CD34
+ cells were cocultured with CD34 2 cells, than in CD34 + -only cell culture ( Figure 4B ). To evaluate the adhesion capacity, we developed a cell adhesion assay. As expected, coculture of CD34 + cells with CD34 2 cells (1.25% CD34 + cells with CD34 2 cells) increased the adhesive capacity compared to that induced by CD34
+ cell culture alone ( Figure 4C) + cell culture, conditioned medium from CD34
+ and CD34 2 cell coculture (1.25% CD34 + cells with CD34 2 cells), or medium alone (as a control), on Matrigel. All subset groups could substantially promote tube formation by HUVECs compared with the control group. Interestingly, EC-derived tube formation was the highest when cells were incubated with the coculture of CD34 + and CD34 2 cells, or the conditioned medium from such a coculture ( Figure 4D ), suggesting the importance of not only cell-to-cell interaction but also paracrine factors from CD34 2 cells in ECderived tube formation. In addition, CD34
2 cells resulted in a better migratory capacity of ECs than serum-and cytokine-free medium or complete EC medium in the Boyden chamber ( Figure 4E ). These findings indicate that CD34 2 cells might play a pivotal role in the functional regulation of EPC-CFUs and ECs through cell-to-cell interaction and paracrine effects.
Contribution of CD34 2 cells to the functional enhancement of transplanted EPC-CFUs in postnatal neovascularization
A previous study revealed that large CFU-EPCs play an important role in the restoration of ischemic diseases [19] . We used a murine hind-limb ischemia model to evaluate the postnatal neovascularization of transplanted large EPC-CFUs. We transplanted CD34
+ cell-derived large EPC-CFUs and mixed CD34 + and CD34 2 cell (1.25% CD34 + cells with CD34 2 cells)-derived large EPC-CFUs into the ischemic sites, and controls were treated with PBS. To assess the recovery of blood flow, the blood flow was measured by laser Doppler perfusion imaging (LDPI) at postoperative day 28 ( Figure 5A ). The recovery of blood flow was significantly improved when mice received mixed CD34
+ and CD34 2 cell-derived large EPC-CFUs, compared with that in animals in any other group ( Figure 5B) . Moreover, immunohistochemical staining for CD31 confirmed that capillary formation was established in the ischemic tissue at postoperative day 28 ( Figure 5C ). Immunohistochemical staining of CD31 was distinctly increased in vessels following transplantation of mixed CD34
+ and CD34 2 cell-derived large EPC-CFUs compared with any other treatment ( Figure 5D ). To explore the engraftment of transplanted large EPC-CFUs, immunohistochemical staining of CD31 and HNA, which specifically labels human cells, was established in the ischemic tissue at postoperative day 28 ( Figure 5E ). CD31 and HNA-positive cells were detected in the ischemic limbs, suggesting the incorporation of transplanted large EPC-CFUs into CD31-positive vessels. The number of HNApositive cells in CD31-positive vessels was increased in mixed CD34
+ and CD34 2 cell-derived large EPC-CFUs compared with any other treatment ( Figure 5F ). These data suggest that CD34 
Identification of the cell population integral to differentiation of EPCs
To identify the essential cell population in the differentiation of EPCs in CD34
2 cell fractions, we performed the EPC-CFA by culturing CD34
+ cells with various fundamental hematopoietic cells including macrophages, T cells, B cells, megakaryocytes, and monocytes. To isolate various hematopoietic cell populations from CD34 2 cells, we first examined the expression of CD3 (a T cell marker), CD11b (a macrophage marker), CD14 (a monocyte marker), CD19 (a B cell marker), and CD41 (a megakaryocyte marker) on CD34
2 cells by FACS analysis. Then, to assess the EPC colony-forming capacity of CD34 + cells, we established an EPC-CFA for CD34
+ cells with cell populations positive or negative for CD3, CD11b, CD14, CD19, and CD41 on CD34 2 cells. Small EPC-CFUs were more significantly increased when CD34 + cells were cocultured with CD3 + cells than any other cell type ( Figure 6A ), whereas large EPC-CFUs were more significantly increased when CD34
+ cells were cocultured with CD11b
+ , and CD14 + cells compared with the other cell types ( Figure 6B ). These results show that T cells may have an essential role in the differentiation of small EPC-CFUs, while macrophages, monocytes, and megakaryocytes may be important in the differentiation of large EPC-CFUs.
Discussion
Although several studies in the last decade have reported the pivotal role of EPCs in ischemic diseases after their initial isolation [1] , the definitive delineation of EPCs remains a challenge due to the lack of a clear hierarchy of differentiation and a defined isolation protocol. Thus, evidence of the efficacy of EPCs in peripheral arterial disease is limited, and the impact of isolated EPCs remains undetermined [27, [34] [35] [36] [37] [38] [39] . The EPC-CFA system allows us to assess the fate and vasculogenic potential of circulating EPCs from primary cells, based on a numerical evaluation of their hierarchical adhesive clonogenicity.
In this study, we performed EPC-CFAs [18] to evaluate the status of EPC development in response to specific interactions with CD34 2 cells, and found that hematopoietic cells support the development of stem cell-derived EPCs. The EPC-CFA was designed to identify EPC-CFUs from CD34
+ cells, an EPCenriched population. Two types of EPC-CFUs derived from CD34 + cells could be identified: ''small EPC-CFUs,'' which are composed of small round-shaped cells with proliferative capacity and are defined as primitive EPCs, and ''large EPC-CFUs,'' which are large spindle-shaped cells with vasculogenic potential and are defined as definitive EPCs [3, 17] . Our previous studies revealed that each EPC-CFU expressed surface markers of the endothelial and monocytic lineages [18] , and that CD34 2 cells increased the expression of endothelial lineage markers, such as VEGFR2, Tie2, and CXCR4 [20] . These results correspond well with our findings in the present study ( Figure S1) + T cells) is critical in the formation of EPC colonies [40] . A previous report using EPC-CFA also showed that development of early EPCs is augmented by an increase in CD14, a monocyte marker, during EPC differentiation [18] . Circulating CD34 + / KDR + cells are generated from circulating multipotent CD34 + cells at platelet-rich sites [41] . In this study, we found that T cells increased the formation of small EPC colonies, which are immature and proliferative EPCs (primitive EPCs), whereas macrophages, monocytes, and megakaryocytes increased the formation of large EPC colonies, which are more mature and functional EPCs, through cell-to-cell interactions and paracrine effects ( Figure 7 ). We then evaluated the contribution of CD34 2 cells to the vasculogenic potential of EPC-CFUs of CD34 + cells in a murine hind-limb model, and found the recovery of blood flow and capillary formation capacity to be significantly enhanced with administration of mixed CD34
+ and CD34 2 cell-derived EPCCFUs, suggesting that CD34 2 cells contribute to the production of proliferative and functionally enhanced EPC-CFUs from CD34 + cells.
To our knowledge, this study is the first to show that hematopoietic cells-which are CD34 2 cells, including macrophages, monocytes, T cells, B cells, and megakaryocytescontribute to the formation of total EPC colonies composed of small and large EPC-CFUs and play a role in the development of the endothelial lineage. Additionally, the optimal proportion of CD34 + cells to CD34 2 cells in EPC-CFA, which produces proliferative and functional definitive EPCs, was found to be as follows: coculture of 1.25% CD34 + cells with CD34 2 cells.
Conclusions
The findings of this study highlight EPC development in response to specific interactions with CD34 2 cells, including hematopoietic cells, through a qualitative and quantitative analysis of EPCs using a clonogenic culture system, the EPC-CFA. Our results suggest that coculture of an optimal proportion of CD34 + cells to CD34
2 cells may assist in the development of a novel cell therapy that surmounts the restrictions of CD34
+ cell yield in highrisk patients and produces effective EPCs. This study provides valuable information to overcome the limitations of cell therapy and may help in the development of more efficient approaches than the ones currently used. Figure S1 Flow cytometric analysis of cell-surface markers in EPC-CFUs. CD34
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